In addition, age, driver mutation type, tumor mutation burden (TMB), and the programmed cell death ligand 1 (PD‐L1) level also affected immune cell infiltration in the early‐stage NSCLC TME. The gene discussed is CD274; the disease is non-small cell lung carcinoma.